In This Article:
Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expected loss per share of $2.91.
Jefferies Biotech Analyst Michael Yee speaks with Brad Smith and Madison Mills on the Morning Brief on Moderna's release, commenting that the drugmaker continues to "[remain] in a very challenging position" as the path to profitability falls out of sight. Spikevax, the company's COVID-19 vaccine, managed to bring in $3.1 billion across 2024.
"While there is the Merck (MRK) cancer vaccine, the Phase 3 CMV vaccine, and the norovirus vaccine, the CMV vaccine has been delayed. The data has not hit, and they sound like they're pushing it out to later this year," Yee says on the other vaccine projects Jefferies is "cautiously optimistic" on.
Yee also comments on the tightening GLP-1 weight-loss drug race between Eli Lilly (LLY), Novo Nordisk (NVO), and Amgen (AMGN).
Related Videos
To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
This post was written by Luke Carberry Mogan.